The discovery of oligopeptides, short chains of amino acids, in the normal central nervous system (CNS) has added a new and at present bewildering scope to our awareness of how the brain and spinal cord regulate their own activity. Precise localizations of these substances have followed the identification of the amino acid sequence of each peptide, the relative ease with which each is synthesized, and the development of progressively more specific antibOdies to each peptide conjugated to a carrier protein as antigen. Two powerful neuroanatomical techniques are in use: (I) Immunocytochemical methods permit light microscopy by the indirect fluorescent technique of Coons (1958) ,or by the peroxidase-antiperoxidase method of Sternberger (1974) and Moriarty (1973) . The addition of osmic acid to the latter method increases the electron density of the reaction products and permits electron microscopy to show details of peptide relationships in the subcellular organelles. The immunoreactive staining does not, however, increase in linear fashion with increased concentration of the peptide.
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(2) Radioimmunoassay does yield quantitative data on concentrations of peptide in frozen specimens of CNS identified and excised under operative microscopy (Kobayashi et al. 1977) . The commonest radiolabels are 3H and 1251. The British investigators Hughes and Kosterlitz of Aberdeen, the Iversens and their collaborators at the University of Cambridge, the groups of Hokfelt of Stockholm, Leeman of Boston and Snyder of Baltimore have made many of these major discoveries.
One of the most clear-cut features of the new data is that nearly every one of these peptides is concentrated at such diverse sites as to connote widely varying functions for each of them. Conversely, each function has associated with it an astounding number of different peptides. To illustrate these points, I have selected a single CNS system -that for pain. The system for some other function might equally well have been chosen.
Prior to the discovery of the neuropeptides, three completely new anatomical systems had been found in the mid-1960s -one for each of the three monoaminergic neurotransmitters serotonin, norepinephrin and dopamine (Dahlstrom & Fuxe 1965 , see Fields & Basbaum 1978 . Each of these systems arising from relatively few cell bodies confined to the brain stem ramifies widely in the brain and cord, but by no means everywhere equally. Akil & Liebeskind (1975) have shown that analgesia in rats produced by electrical stimulation of the mesencephalic periaqueductal gray matter is potentiated by increased levels of dopamine as well as of serotonin. Conversely, such stimulation-produced analgesia is suppressed by increased levels of norepinephrin. The best-studied example of a mechanism for serotonin's suppression of pain is the pathway arising in the bulbar nucleus raphe magnus (NRM) (Dahlstrom & Fuxe 1965) . The projection of a descending serotonergic system from this nucleus via the dorsolateral funiculus of white matter to the dorsal horns of the cord has been confirmed by both anterograde and retrograde staining techniques (Brodal et al. 1960 , Basbaum & Fields 1977 , Carlsson et al. 1964 ) and by physiological methods (Engberg et al. 1968a , b, c, Jordan et al. 1978 , Oliveras et al. 1979 ). Rexed's laminae I (marginal zone), II substantia gelatinosa and IV, V, VI contain the secondary afferent neurons excited exclusively or partially by noxious stimuli. It is in these laminae and the corresponding parts of trigeminal nucleus caudalis that the heaviest terminal fields of the NRM projections are found (Berman 1968 ). Stimulation of NRM inhibits those dorsal hom neurons responding to noxa (Fields et al 1977 , Willis et al. 1977 , Beall et al. 1976 ) and this inhibition is mediated by serotonin (Clineschmidt & Anderson 1970) . Convincing evidence for another anti-nociceptive descending bulbospinal and bulbotrigeminal system mediated by norepinephrin has been adduced by three groups of workers (Sasa et al. 1974 , Takagi et al. 1979 , Yaksh 1979 .
In addition to the foregoing bulbar and cord sites concerned with pain, there is extensive evidence that pain may be suppressed by stimulation in (a) the ventrolateral aspect of the midbrain periaqueductal gray matter in animals, and (b) the posterior inferomedial thalamic area in man (Mazars 1976 , Hosobuchi et al. 1973 , Richardson & AkilI977, Lewis & Gebhart 1977 , Mayer et al. 1971 , Reynolds 1969 . There is some evidence that analgesia occurs on stimulation of (c) the septal area (Breglio et al. 1970 , Go11967, Schmidek et al. 1971 , Heath & Mickle 1960 , (d) the amygdala, and (e) the caudate nucleus (Mark & Ervin 1969) . The nucleus gigantocellularis in the medial bulbar reticular formation is also related to pain (Casey et al. 1974) . Lesions in the thalamic dorsomedial, intralaminar or pulvinar regions, or in hypothalamic peri ventricular or posteromedial regions, may also stop severe pain in man (Fairman 1976) . It is to these areas that I shall be referring in the subsequent discussion, although at this stage of our ignorance the presence of a peptide in an area which is or may be related to pain is not, of course, decisive evidence that the substance is concerned with pain or indeed any other modality of sensation. The proof of such relationship requires critical physiological studies.
The demonstration of serotonin, dopamine and norepinephrin as neurotransmitters related to pain as well as to hosts of other functions was added to data on other small molecular neurotransmitters -such as acetylcholine, epinephrin, glycine, gamma-aminobutyric acid (GABA) and glutamate -making a plethora ofneuroregulatory chemicals.
At this juncture, when the last thing we seemed to need was more internal neuroregulators, the neuropeptides have burst on the scene. There are at least three groups of them. In each group some are probably related to pain: (I) those which bind to the brain's opiate receptors, met-enkephalin, leu-enkephalin and the a-, pand ')I-endorphins; (2) those originally described in relation to action on the smooth muscle of blood vessels and viscera, substance P, angiotensin II and cholecystokinin; and (3) those identified in the hypothalamus in the search for hypothalamic releasing factors for pituitary hormones, somatostatin and neurotensin.
Enkephalins (ENKs) When structures were found in the brain which have a high capacity to bind morphine and other narcotics stereospecifically, this set in motion a competition to find the brain's own endogenous substance or ligand for which these so-called opiate receptors had presumably evolved. Hughes (1975) , now at Imperial College in London, won the race by astute use of bioassay systems involving neurogenic contractions of the mouse vas deferens and guinea pig ileum. He and his colleagues identified the two similar pentapeptides they have called metand leu-enkephalin, but showed that they occurred in many areas of the brain which are unrelated to pain as far as we know ). Hence they wisely chose designation by a word which is noncommittal with respect to function. Hughes also drew attention to the fact that his pentapeptide with methionine at the COOH terminal end has the same amino acid sequence as the acids 61-65 in the much larger peptide called p-endorphin (amino acids 61-91 in p-lipotropin). The endorphins have been found in the pituitary gland, the structure in which P-lipotropin occurs. These substances also bind to the opiate receptors. Using radioimmunoassays, Simantov et al. (l977a) soon confirmed (Table 1) the main points made by Hughes, and drew attention to the fact that pronounced regional variations in concentrations of enkephalin do not always correlate well with opiate receptor binding. Thus by far the highest concentrations of enkephalin are in the corpus striatum and globus pallidus, whereas the amygdala and periaqueductal gray have the highest density of opiate receptors. This suggests that the enkephalins have other than narcotic functions. In the absence of any method to show the precise cellular locus of the 'opiate receptor', no definitive statement can be made as to how and where enkephalins' actions are mediated at cellular level.
Unlike the smaller molecules acting as neurotransmitters which are synthesized at the nerve terminals, the neuropeptides are synthesized in the neuronal cell bodies and transported via the axon to the terminals. Demonstration of the peptide in the cell bodies has been facilitated by pretreatment of the animal with colchicine, which stops axonal transport out of the cell body. The densest staining of fibres is in lamina II, the substantia gelatinosa of the dorsal horn of the cord -the area directly concerned with integration of incoming impulses related to sensations including pain. The same staining occurs in a few cells in laminae II, IV, V and VI of the dorsal horn, which contain the so-called polymodal neurons responding to both noxious and non-noxious stimuli. Enkephalin-containing neurons have been found immunocytochemically in every region of the brain except the cerebral and cerebellar cortices. Confirming their relation to pain is their presence in the substantia gelatinosa of nucleus caudalis of the trigeminal nuclei in the brain stem, in the nuclei raphe magnus and raphe pallidus, in the ventrolateral aspects of the periaqueductal gray, the lateral septal nucleus, the central nucleus of the amygdala, the dorsomedial and intralaminar thalamus, the periventricular hypothalamus, the caudate nucleus, the locus ceruleus, and the ventromedial parts of the nucleus reticularis gigantocellularis (Hokfelt et al. 1977 a, b, Simantov et al. 1977b , Sar et al. 1978 . The enkephalin positive cell bodies in these areas probably represent interneurons.
The concentration of en kephalin-like material in synaptosomes intimates that it has a neurotransmitter function (Simantov et 01. 1978) .This is further suggested by the fact that the two enkephalins are so rapidly degraded in vivothat behavioural analgesic effects are transitor) and require huge doses for their demonstration. Thus intracerebroventricular injections of met-ENK in mice require 75 times the dose of morphine for the same analgesic effect, which with the ENK lasts barely 5 minutes.
When given iontophoretically into the substantia gelatinosa, the main effect of the two ENKs is to reduce the responses of the cells to noxious stimuli only, leaving unaffected the responses to innocuous stimuli. This effect is reversed by small doses oflV naloxone, indicating that the ENK is probably acting here on opiate receptors (Duggan et 01. 1977) . Lesion experiments have shown that the enkephalin neurons in the dorsal horn are intrinsiC interneurons (Hokfelt et 01. I977b) . Microiontophoretically applied ENK also depresses spontaneous and glutamate-enhanced firing rates in the periaqueductal gray and the caudate nucleus in over 90% of the responsive cells (Gent & Wolstencroft 1976 , Ziegelgansberger & Fry 1976 .
As with many of the other peptides, attempts have been made to modify the native enkephalin so that it would retain its desired physiological effect but not be degraded promptly by the ubiquitous carboxy-and aminopeptidases. A recent one of the many hundreds of analogues developed prevents the aminopeptidase activity at the amino end of the chain by use of D-alanine instead of t-glycine in position 2, prevents hydrolysis in the middle of the chain by methylating the amino group of the phenylalanine and oxidizing the methionine to a sulfone. Although this compound had long-lasting potent analgesic effects in animals (Roemer et 01. 1977),a trial in 40 healthy human volunteers revealed a host of undesirable side effects in every one of them at doses one-tenth to half of those anticipated from the animal studies to be appropriate for man. None of the clinical effects were expected; they were not morphine-like and they were not prevented by the opiate antagonist nalorphine (von Graffenreid et 01. 1978) . When the agent was given to 9 schizophrenics, 5 of them had as a side effect pain in the head and neck (Jorgensen et 01. 1979 )!An analogue degraded slowly enough to be of practical value which retains a major analgesic effect has yet to be developed.
p-endorphin
When applied iontophoretically, p-endorphin specifically depresses nociceptive cells in the posterior horns of the eat's spinal cord, leaving most non-nociceptive units unaffected (Henry 1978) . It has both profound analgesic and dramatic catatonia-inducing effects upon intracerebroventricular injection in animals. Three groups of workers have obtained somewhat disappointing degrees of pain relief upon intravenous or even intracerebroventricular injections in man (Cetlin et 01. 1977 , Foley et 01. 1978 , Hosobuchi et 01. 1979 .I interpret recent studies of Bloom et al. (1978) and of Watson et 01. (1977, 1978) as indicating that the endorphins, named with the assumption that they are the body's own morphine, may have a meagre in vivo relation to pain. Antisera to p-endorphin localize in the rat only in neuronal perikarya in basal tuberal hypothalamus and no other cells in the rat brain. Their large varicose nerve fibres go only to a few midline nuclear areas in diencephalon, to dorsal and ventral periaqueductal gray and down to the anterior pons. Moreover, p-endorphin reactive nerve fibres are traceable for hundreds of micrometres as thick round beads, whereas the enkephalin-reactive fibres are mainly isolated tiny dots traceable for no more than 100 jJ.m. At least at the level of the primary afferent neurons we associate only the finer fibres with impulses for pain (Sweet 1976).
However, the following contrary evidence in man argues for a significant pain suppressor role for this chemical. p-endorphin-like immunoreactivity increased from 13 to 30-fold in human third ventricular cerebrospinal fluid in 5 patients within 5 to 15 minutes after the beginning of electrical stimulation in the posteroinferomedial thalamus. Such stimulation gave significant or complete relief of intense pain in all 5 patients (Akil et 01. 1978) . Slightly less dramatic increases in 3 patients studied similarly were recorded by Hosobuchi and colleagues (1979) . The increases were from 2 to 7-fold. They had 3 other excellent control patients whose different type of deafferentation pain was being treated via electrodes placed more laterally 15-20 mm from the midline. No changes in intra-third-ventricular cerebrospinal fluid occurred after the 15 minutes of stimulation on these patients. Stimulation gave all 6 patients significant or complete relief from their severe pain.
Although the p-endorphin terminals are much more sparse than those for all other known neuropeptides, it is possible that their functions are also more circumscribed and more concentrated upon suppression of pain, so that a more direct application of this compound to human pain problems may be feasible than has proven to be the case to date with enkephalins.
Substance P (SP) Immunohistochemical studies quickly followed the synthesis of pure SP by Chang & Leeman in 1970 and demonstrated it in high concentration at many sites except for most of the neocortex and cerebellar cortices (Ljungdahl et al. 1978a , b, Hokfelt et 01. 1977a , b, 1978a , b, Cuello et al. 1978 , Cuello & Kanazawa 1978 . The latest comprehensive accounts confirm its neuronal location in the following areas definitely related to pain: (1) 20-25% of the smaller cell bodies of the posterior root ganglia projecting to substantia gelatinosa of spinal cord and trigeminal nucleus caudalis; (2) raphe pallidus and raphe magnus with descending projections into the spinal cord; (3) ventral periaqueductal gray; (4) a few in laminae I-VI of the posterior horns of the cord. (The sparse distribution in neuronal cell bodies in the dorsal horns, 0-5 cells per section in the rat, contrasts with its dense distribution in nerve terminals and axons especially in the superficial layers (Ljungdahl et al. 1978a ).) Its locus in neurons in the following areas might be related to pain: (1) dorsal and medial raphe nuclei projecting to the telencephalon; (2) medial amygdaloid nucleus projecting to central amygdaloid nucleus; (3) septal area, external and internal groups.
SP is formed in the cell bodies and transported in axons both central and peripheral to the posterior root ganglia. It is greatly reduced in substantia gelatinosa both of the posterior horns and of trigeminal nucleus caudalis 10days after posterior rhizotomy and at the periphery after neurectomy . Dorsal root section leads to a supersensitivity response of related spinal cord interneurons to an SP analogue. This suggests that an increase in numbers of SP receptors may occur upon loss of its input into the cord. Various degrees of this supersensitivity may account for the dysaesthesias or anaesthesia dolorosa after posterior rhizotomy in man. The axonal transport of SP occurs within vesicles (Hokfelt et al. 1977a) . The somatofugal transport rate has been measured at 1-2 mm/hour in the cervical vagus, a rate similar to that found for the synthetic enzymes tyrosine hydroxylase and dopamine hydroxylase (Gilbert & Emson 1978) .
That SP is specifically related to pain is indicated by the disappearance of SP-containinñ erve endings in trigeminal nucleus caudalis after removal of the tooth pulp in cats. Tooth pulp is innervated almost exclusively by nociceptive afferents. Both in spinal dorsal hom and in trigeminal nucleus oralis and caudalis only those cells which respond to noxious stimuli are excited by iontophoretic application of SP (Henry 1976 (Henry , 1978 . Moreover, it is found only in the A delta and C fibre sizes -the ranges of fibre diameter related to impulses for pain. It is generously distributed in free endings in the skin but does not occur in secondary afferent nuclear groups known to be unrelated to nociception, namely trigeminal nucleus oralis and the nucleus gracilis and cuneatus.
That it is indeed a neurotransmitter is indicated by its concentration not only in synaptosomal fractions of brain (Ryall 1964) , but also within synaptic vesicles of nerve terminals of the dorsal hom as seen in the electron microscope (Cuello et al. 1977 ). In most neurons tested, metabolic degradation rather than tissue reuptake causes an excitation slow in onset and protracted in duration (Nicoll 1976) . This fact plus its lack of reuptake have led Mroz & Leeman (1977) to hypothesize that it serves as a 'vicinal transmission enhancer', and that its abnormal accumulation may cause hyperpathia. Its release from peripheral sensory nerve endings may also produce reflex vasodilation .
In general, ENK suppresses and SP promotes pain. Henry et al. (1975) were the first to show that SP applied by microiontophoresis excites dorsal hom neurons activated by noxious stimuli. However, in small doses SP intraperitoneally or intracerebrally may produce analgesia (Frederickson et al. 1978 , Mohrland & Gebhart 1979 .The complexity of the action is further indicated by the work of Jessell et al. (1978) and ofYaksh (1979) . The former workers found that administration of capsaicin produces striking depletion of SP from primary sensory Sp neurons. The latter study showed that the prolonged depletion associated with chronic administration of the drug is associated with elevation of the animal's pain threshold only to thermal and chemical and not to mechanical noxae. Hence it was concluded that SP may mediate responses of pain only to thermal and chemical injury (Reddy & Yaksh 1980) . A graphic illustration of the correspondence in location of SP and ENK in the cord and brain stem has been given by Hokfelt er al. (l977b) . Both are present not only in cell bodies and nerve terminals in the dorsal hom and trigeminal nucleus subcaudalis, but also in nuclei raphe magnus and pallidus and in the ventral and lateral parts of the periaqueductal gray. That they do in fact interact was demonstrated by Jessell and Iversen's (1977) study of the K+ eVoked release of SP from bulbar trigeminal nerve nuclei of the rat which were dissected from fresh brain stems and pooled. This release of SP was inhibited not only by the met-enkephalin analogue [D-AlaF-met-enkephalin amide, but also by p-endorphin and by morphine. Further evidence of the complexity of the neurochemical interactions is provided by the fact that the pain suppressor, serotonin, is also high in concentration in these same areas -amygdala, periaqueductal gray, raphe nuclei and substantia gelatinosa. In fact, certain individual painrelated bulbar neurons contain both serotonin and SP. These lie in the raphe nuclei magnus, obscurus and pallidus (Hokfelt et al. 1978a , Chan-Palay et al. 1978 . Mudge et al. (1979) have found that GABA, norepinephrin, serotonin and an ENK analogue all inhibit the K+ evoked release of SP from dorsal root ganglionic neurons grown in culture, and that both these substances and ENK decrease the action potential recorded from these cell bodies. The inference is that in vivo these neurotransmitters may all have a presynaptic inhibitory action at the axonal terminals of the SP fibres as they lie in the posterior hom of the cord.
Somatostatin (SaM)
The tetradecapeptide somatostatin, originally identified as the hypothalamic hormone inhibiting the release of somatotropin, the pituitary growth hormone, proves to have many other inhibitory effects. After iontophoretic application to individual brain cells, it decreases the spontaneous firing of many cerebral and cerebellar neurons (Renaud et al. 1975) . This occurs in those neurons of the dorsal hom of the cord activated by noxious stimuli (Randic & Miletic 1978) . A suppressor action on various aspects of behaviour and a prolongation of anaesthesia and sedation have been reported by Segal & Mandell (1974), Brown & Vale (1975) and Vale et al. (1977) . The potent excitatory responses elicited by somatostatin on pyramidal cells in the rat hippocampus, described by Dodd & Kelly (1978) , are unlikely to be related to pain.
Neurochemical studies intimating a neurotransmitter role for SaM include the following facts: it is concentrated in synaptosomal fractions and in synaptic vesicles (Berelowitz et al. 1978) ; it is released from slices of rat hypothalamus and amygdala in a calcium-dependent fashion (Iversen et al. 1978) and high potassium releases it from hypothalamic synaptosomes.
The many functions of SOM in the CNS are attested by the occurrence of 90% of it outside the hypothalamus. Although by far the highest concentration is in the medial basal hypothalamus (73.1 ngjmg protein; Kobayashi et al. 1977) , immunohistochemical techniques in the hands of colleagues (1976, 1978b) show immunoreactive neurons in many sites including amygdala and the smaller cell bodies in the posterior root ganglia. In this latter site it is not in the same cells as substance P ). SaM-positive nerve terminals also occur in many places including the amygdala, the septal region and the terminations of the posterior roots in the substantia gelatinosa of trigeminal subnucleus caudalis and dorsal hom of the cord. SOM (like SP) flows from its site of origin in the ganglionic cells of the primary afferent neurons to the termini in substantia gelatinosa, as demonstrated by its disappearance from these termini after posterior rhizotomy and accumulation in the rootlets peripheral to the cut (Elde et al. 1976) . SOM also concentrates in two other regions possibly related to pain, the septal area (1.9 ng/mg protein) and in the amydgala (3.7 ng/mg protein) (Kobayashi et al. 1977) .
Neurotensin (NT)
That neurotensin, angiotensin II and cholecystokinin influence pain is not yet proven, but such action is suggested by the anatomical evidence for all three. There is also some physiological evidence of a relationship to pain for neurotensin. This tridecapeptide, isolated originally in Leeman's laboratory, has the typical diversity of anatomical sites of concentration indicative of relation to many functions. These features of its behaviour are characteristic for a neurotransmitter: it is enriched in synaptosomal and microsomal subcellular fractions (Uhl & Snyder 1976) ; it is released from hypothalamic slices by depolarizing concentrations of external potassium in a Catt-dependent fashion (Iversen et al. 1978) ; its brain tissue stores remain stable during superfusion; and it binds to synaptic membranes in a highly specific, saturable and reversible fashion (Kitabagi et al. 1977) . The immunofluorescence studies of both the Hokfelt and Snyder groups show it to be concentrated in the substantia gelatinosa of the spinal cord, trigeminal nucleus caudalis and in the ventral portions of the periaqueductal gray matter. Radioimmunoassays (Kobayashi et al. 1977) confirm the presence of a high concentration of neurotensin in the periaqueductal gray (0.75 ng/mg protein). Neurotensin fibres and cell bodies are clustered toward the medial edge of the substantia gelatinosa of the caudal trigeminal nucleus, whereas enkephalin concentrates preferentially in the lateral aspects of this nucleus (Uhl et al. 1978) . Neurotensin is also in the norepinephrin-secreting locus ceruleus and in cells in the central nucleus of the amygdala, which are the sites of origin of an amygdalofugal pathway via stria terminalis for both neurotensin and enkephalin (Uhl et al. 1978) . Neurotensin is also concentrated in the septal area (0.68 ng/rng protein) (Kobayashi et al. 1977) . Its administration intracisternally in mice inhibits their responsiveness to noxious stimuli (Clineschmidt & McGuffin 1977) . Iontophoretic application to neurons in laminae I-III of the eat's dorsal hom excites all categories of neurons; the action is not confined to those related to noxious stimuli (Miletic & Randic 1978) .
Angiotensin II Angiotensin II, an octapeptide formed by the angiotensin-converting enzyme from the inactive decapeptide angiotensin I, is the most powerful vasopressor molecule known (Fischer-Ferraro et al. 1971) . However, when injected into the specific appropriate regions of the hypothalamus it produces either drinking of water, a release of vasopressin or rises in blood pressure. Although neurons immunoreactive to angiotensin II have been demonstrated to date only in certain hypothalamic nuclei, immunoreactive nerve terminals occur in many sites in the brain and spinal cord except for cerebellum and neocortex (Fuxe et al. 1976 ). Receptor binding sites for angiotensin II have been localized to synaptosomes by 12sI-binding assays. These assays have also shown that such binding to brain membranes is saturable and reversible (Bennett & Snyder 1976) .
A relationship to pain is intimated by the high densities of immunoreactive nerve terminals both in the substantia gelatinosa of the spinal cord and of trigeminal nucleus caudalis. Such a relationship is also suggested by high densities of these terminals in the central amygdala and by moderate densities around the locus ceru1eus. Just as occurs with substance P, the immunoreactive stain to angiotensin II disappears from the dorsal hom after posterior rhizotomy, but accumulates in the distal part of the root still connected to the posterior root ganglion.
Cholecystokinin This latest entry in the neuropeptide substantia gelatinosa sweepstakes is the truncated fonn of the 33 amino acid cholecystokinin, originally isolated from the gut by Said & Mutt (1970) . It is principally the octapeptide form which separates out chromatographically from the brain; smaller amounts of CCK-33, CCK-12 and CCK-4 are also present. CCK-8 applied iontophoretically to hippocampal pyramidal cells excites them by direct action on receptors on the cell body rather than by a synaptic mediation. However, CCK-8 is concentrated in synaptosomes and can be released by stimulation of cerebral cortical slices (Emson et 01. 1980) . The cerebral cortex contains very large amounts of CCK-8 (500 pmol/g in the pig), far higher than any other neuropeptide studied to date. Because so much of the brain is cerebral cortex, this makes CCK-8 by far the most abundant CNS peptide yet discovered. The immunoperoxidase stain reveals it in normal cell bodies of all layers of the cortical gray (Straus et af. 1977) , but the most densely packed collection of CCK-8 cells in the brain is in the ventral part of the periaqueductal gray. They lie ventral to the aqueduct near to but not in the midline. Another dense group of these cells is in the midline of the caudal portion of the dorsal raphe nucleus, also noted for its serotonin cells. Although the amygdala and especially its central nucleus contain many fibres, there are no CCK-8 cells therein (Innis et af. 1979) . Especially pertinent to the thought that this neuropeptide may be related to pain is its occurrence in the small neurons of the posterior root ganglia, but in different neurons from those for substance P or somatostatin (Rehfeld et al. 1979) . Like these two peptides, CCK-8 densely stains fibres in the dorsal hom's lamina II (Emson, personal communication) . However, physiological studies with regard to pain have not yet been done.
Conclusion
We have recently learned from a major aviation accident that backup systems can be vitally useful. The Boeing 747 with 5 hydraulic systems and the Lockheed Tristar with 4 such systems have not crashed due to an engineering failure, whereas a plane with only 3 such systems has met disaster (Time 1979) . We are becoming daily aware that our central nervous systems have long since achieved this sound principle of design -that there are many neurochemical mediators of excitation or suppression at a given site overlapping in function (see final sentence on Substance P). A single additional example will suffice.Thus far 9 neurotransmitters have been identified in the afferents to the norepinephrin-secreting locus ceruleus (A6 cell group of Dahlstrom & Fuxe 1965) . These are GABA, epinephrin, substance P, enkephalin, angiotensin II, thyrotropin releasing hormone (TRH), vasoactive intestinal peptide (VIP) and serotonin (Hokfelt 1979, personal communication) , as well as neurotensin (Uhl et al. 1978) . There is no evidence however that any two of these substances are brought into play by identical means or have identical mechanisms of action.
A multiplicity of controls means that every time we perturb a system in a desired direction there are several mechanisms which may move toward restoration of the status quo ante and thwart our therapy. Such mechanisms are doubtless responsible for the tachyphylaxis to medications and the reappearance of algesia and clinical pain which tend to follow initially successful neurosurgical procedures. Conversely, we may maintain a good result once achieved by not one but several substances normally formed as well as any analogues and/or potentiators which we can design. Here, too, one sees a role for functional neurosurgery to introduce to the proper site in the brain that neuropeptide or other neurotransmitter which must depend for its effect not only on its chemical nature but also on the precise anatomical substrate upon which it acts.
